Abbott (NYSE:ABT) said today that it inked a deal with Carl Zeiss Meditec (ETR:AFX) that will see it sell Zeiss cataract surgery products alongside its own such offerings in the U.S.
"This comprehensive offering, including synergistic diagnostics, visualization systems, lens extraction systems, and intraocular lenses, provides surgeons with access to a complete cataract surgery portfolio to assist them in maximizing visual outcomes and streamlining patient flow," Abbott said in a press release.
In a separate announcement, Abbott said it won 510(k) clearance from the FDA for its Cataract Operating System 3 and the Liquid Optics Interface 12, both of which are used with its Catalys precision laser system.
"Together with surgeons, Abbott is committed to delivering unsurpassed visual outcomes to patients," Abbott Medical Optics senior vice president Murthy Simhambhatla said in prepared remarks. "Our collaboration with Zeiss further demonstrates our commitment by expanding our portfolio and providing our customers a unique and comprehensive cataract solution."
"Surgeons should have the choice of the best and most innovative products to maximize clinical outcomes, manage their data, and optimize their workflow," added Carl Zeiss Meditec president & CEO Dr. Ludwin Monz. "That is why we agreed to expand our customer reach in the United States by making our products available additionally through Abbott."